MedTrace Logo

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2014-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis (\[AD\]; skin rash, inflammation) that is moderate in severity.

Conditions

Interventions

DRUG

Placebo

Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.

DRUG

JNJ-26113100 (50 mg) once daily

JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.

DRUG

JNJ-26113100 (100 mg) once daily

JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.

DRUG

JNJ-26113100 (100 mg) twice daily

JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.

DRUG

JNJ-26113100 (250 mg) twice daily

JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development L.L.C Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455429 on ClinicalTrials.gov